Update on Drugs and Drug News: Number 3 2000

Updates on: 5-fluorouracil 5-FU Microsponge Interferon-Alpha Veldona Hydroxyurea Amprenavir Agenerase Diclofenac Sodium Solaraze

Cosmetics to Imitate a Summer Tan

This article will focus on cosmetic products that are designed to simulate tanning of the skin by coloring or staining the skin without sun exposure. The cosmetics may or may not contain a sunscreening agent, but the color produced is not protective. Certainly, a cosmetic tan is safe alternative for patients who use a tanning booth or worship the sun.

Systemic Therapy of Psoriasis Using Methotrexate

If methotrexate were introduced as a new drug today, it would be hailed as a major advance in the management of psoriasis, as well as for a number of other conditions. When patients are properly screened and educated about the correct use of this drug, and appropriately monitored during treatment, MTX is often very safe, simple to use, inexpensive, and well-tolerated.

Update on Drugs and Drug News: Number 2 2000

Updates on: Estradiol Transdermal System Vivelle Levofloxacin Tablets/Injection Levaquin Tablets/Injection Tretinoin Cream Renova 0.02% Tretinoin Cream Renova 0.05% Butoconazole Nitrate Gynazole 2% vaginal cream Docosanol 10% Cream Tacrolimus Ointment

US FDA Advisory Committee Meetings Held to Discuss Isotretinoin, Safety Issues and a New Accutane Formulation

There is no drug that has provided as much therapeutic benefit for 12 million acne patients as this retinoid has done in the past 18 years following its introduction. However, it is a retinoid and, therefore, a teratogen.

Perspectives on Isotretinoin and the Canadian Consensus Guidelines on Treatment of Acne

Treatment objectives and pharmacoeconomic considerations are important when developing guidelines that are effective and rational. Canadian Acne Treatment Guidelines were last published in 1995. New guidelines were recently developed to incorporate therapeutic advances and data from more recent studies.

Update on Drugs and Drug News: Number 1 2000

Update on: Clobetasol propionate Olux Foam 0.05% Alitretinoin 0.1% gel Panretin Graftskin Apligraf Bexarotene 1% gel Targretin 10% Docosanol Cream Bleomycin ANDA

Treatment Options For The Cutaneous Manifestations Of Systemic Sclerosis

Systemic sclerosis is a multisystem disorder with vascular instability as a clinical hallmark. Treatment currently consists of recognition and management of end-organ damage.

Ciclopirox Nail Lacquer Topical Solution 8%

Ciclopirox nail lacquer 8% (Penlac, Aventis Pharma) was approved by the US FDA in December 1999, as a component of a comprehensive management program, for use in immunocompetent patients who have mild to moderate onychomycosis of the fingers and toes without lunula involvement due to Trichophyton rubrum.

Update on Drugs and Drug News: June, 2000

Update on: Paclitaxel Paxene Testosterone Gel AndroGel 1% “Intelligent” Dressing Acemannan Hydrogel Cyclophosphamide 25mg and 50mg tablets Ketoconazole 2% Cream Halofuginone OTC Vaginal Preparations Clotrimazole 2% Three Day Vaginal Cream Cyclosporine Gengraf Apligraf Graftskin

Current Therapy in Behçet’s Disease

Behçet’s disease is an inflammatory disorder of unknown cause. There is often involvement of the gastrointestinal system, the central nervous system and large vessels, which can be life-threatening. As well, ocular lesions can cause blindness. Mucocutaneous symptoms are self-limiting but more frequent.

Vitiligo Management Update

Vitiligo is an acquired skin disorder caused by the disappearance of pigment cells from the epidermis, and results in well defined white patches that are often symmetrically distributed. The lack of melanin pigment makes the lesional skin more sensitive to sunburn.

Update on Drugs and Drug News: May, 2000

Update on: Bexarotene Capsules Targretin Temozolomide Temodal Mequinol 2%/Tretinoin 0.01% Solage Linezolid Zyvox Amphotericin B Liposome for Injection Ambisome Terbinafine HCl 1% Solution Lamisil

DPCP for the Treatment of Alopecia Areata

Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice by many dermatologists. Although there have been no major side effects reported since its initial use, there remain some unknowns regarding its safety.

Systemic Drugs With Antipruritic Potency

There are no specific antipruritic drugs on the market, but there are a high number of case reports and experimental investigations describing medications with antipruritic potency. It is therefore the aim of this article to review the major systemic antipruritic drugs and give a short overview on the different types of pruritus.

Update on Drugs and Drug News: April 2000

Update on: Estradiol Vaginal Ring Estring Allegra Piperonyl Butoxide/ Pyrethrins Rid Mousse Temoporfin Foscan

Herbal Anti-Inflammatory Agents for Skin Disease

Herbs have been used in clinical medicine for thousands of years. However, it is only in recent times that we have been able to employ scientific methods to prove the efficacy of many of these herbs and to give us a better understanding of their mechanisms of action.

Rising Drug Costs: The Impact on Dermatology

In the US prescription drug costs are rising faster than any other component of health care expenditures, and show no signs of slowing. Factors driving the rise in prescription drug costs include the introduction of new drugs, and consumer demand. (*Title Incorrect in STL Original--check--change link name)

Update on Drugs and Drug News: March, 2000

Update on: Tissue Engineered Collagen Matrix Oasis Wound Dressing Bexarotene Targretin Gel 1% Eflornithine Hydrochloride Vaniqa Cream 15% Biologically Active Dressing Composite Cultured Skin (CCS) Famciclovir Famvir Moxifloxacin Avelox/Avalox Finasteride 1mg Tablets Propecia

Drug Treatments For Skin Disease Introduced in 1999

Drug Treatments For Skin Disease Introduced in 1999

Synopsis of Laser Assisted Hair Removal Systems

Conventional treatment options for hypertrichosis and hirsutism are tedious and time consuming. Laser hair removal offers an efficient way to permanently reduce excessive hair growth.

Update on Drugs and Drug News: February, 2000

Update on: Aminolevulinic Acid Levulan Photodynamic Therapy G-3139 Genta Inc Moxifloxacin HCl Avelox Ciclopirox Loprox 8% Topical Solution 5-fluorouracil Solex Allovectin-7 Vical Inc

Treatment Options For Localized Scleroderma

Localized scleroderma, or morphea, is a chronic disease that causes a thickening and induration of the skin. For plaque type morphea, the treatments include super-potent corticosteroids and calcipotriol. For the more generalized forms, as well as the linear forms, UVA is currently the best therapeutic modality.

Update on Drugs and Drug News: January 2000

Update on: Pyrethrins/Piperonyl butoxide Rid aerosol foam mousse Fluocinolone acetonide 0.01% Derma-Smoothe/FS Quinupristin/ Dalfopristin Synercid IV Rid Lice Egg Loosener Gel Tacrolimus Protopic Ointment Docosanol

Update on Topical Acne Treatments

Topical acne treatment can positively benefit patients with acne. This review summarizes clinical and prescribing information on currently available topical agents. The efficacy of the medications included in this report is supported by properly designed randomized clinical trials.

Current Treatments for Scabies and Pediculosis

Scabies and lice have afflicted man since ancient times. Permethrin is generally the treatment of choice for head lice and scabies, because of its residual effect. Toxicity and absorption are minimal. Ivermectin should be reserved for cases where permethrin fails.

Update on Drugs and Drug News: May, 1999

Update on: Alendronate Fosamax Alitretinoin Panretin Gel 0.1% Malathion Ovide 0.5% Lotion Abacavir Sulfate Ziagen Interferon alpha-2a Roferon-A Lidocaine Patch 5% Lidoderm Pexiganan acetate Locilex cream 1% Aminolevulinic acid Levulan Photodynamic Therapy Ketoconazol Teva Antiviral Agents Antirejection Therapy

Electrolysis For The Treatment Of Hypertrichosis And Hirsutism

There are three electrolysis modalities. In galvanic electrolysis, a direct electric current is passed down a needle inserted into the hair follicle, destroying the follicle. In thermolysis a high frequency alternating current is passed down the needle and produces destructive heat.

New Corticosteroids

Corticosteroids have dominated the class of anti-inflammatory agents for the past 50 years. In the last ten years, new corticosteroids have been developed for topical use. Characteristics common to these several chemically different corticosteroids are their class III, or high potency designation and their improved safety profile.

Update on Drugs and Drug News: April, 1999

Update on: Mupirocin Bactroban® Roxithromycin Rulid® Temoporfin Foscan®Fluticasone propionate Cutivate® Cream 17-Beta-Estradiol Vagifem® Itraconazole injection Sporanox® IV injection Becaplermin Regranex® Gel 0.1% Lidocaine/prilocaine EMLA® cream

Soft Tissue Augmentation with Silicone

Adatosil® is a viscous silicone oil which was granted FDA approval in 1994. This designation removes the legal obstacles to usage for soft tissue augmentation. However, physicians are advised to exercise discretion when using this product.

N-2-butylcyanoacrylate (GluStitch™)

Cyanoacrylates are surgical adhesives that provide another option for wound closure. There are a number of surgical adhesives either currently available or under development. The presently available butylcyanoacrylates and octylcyanoacrylates are reviewed.

Update on Botulinum Toxin

Botulinum toxin type-A (BTX-A) is a neurotoxin which blocks presynaptic release of acetylcholine. It interferes with neuromuscular transmission, temporarily paralyzing the affected muscle. Of special interest for dermatologists is the unlabelled cosmetic applications, for conditions such as wrinkles and hyperhidrosis.

Update on Drugs and Drug News: March, 1999

Update on: Methoxsalen Uvadex Becaplermin 0.01% Regranex®Aldesleukin Proleukin®Post-herpetic neuralgia Lidoderm® patch Betamethasone valerate foam Luxiq® 0.12% Paclitaxel Taxop®Dietary supplements, Temozolomide Temodal®Terbinafine HCl cream 1% Lamisil®

Psoriasis Treatments Under Development

A review of this list of agents that are presently undergoing clinical trial. Although only a few of the drugs on this list will gain regulatory approval, what is exciting is the likelihood that some new agents will be approved and will radically alter the way we treat psoriasis.

Focus on Diane-35®

Diane-35®, known as Dianette® in some countries, is a combination of cyproterone acetate 2 mg and ethinyl estradiol 0.035 mg. It has recently received regulatory clearance in Canada, but has not yet been approved by the US FDA.

Update on Drugs and Drug News: February, 1999

Update on: Imiquimod Aldara® Cream Abacavir Ziagen® Finasteride 1 mg tablets Propecia® Lyme disease vaccine LYMErix®Aldesleukin Proleukin®Varicella Vaccine Varivax®Minoxidil Taisho

Drug Treatments Introduced in 1998

Drug Treatments Introduced in 1998

Drugs that may exacerbate psoriasis

This review concentrates on those drugs which have been clearly shown, or are widely reputed, to make psoriasis worse. There is insufficient clinical evidence to justify the inclusion of many drugs which have been included in published lists of drugs said to exacerbate psoriasis.

Update on Drugs and Drug News: January, 1999

Update on: Lidocaine 2.5%, prilocaine 2.5% Emla® patch Cyclosporin SangCya®Metronidazole lotion 0.75% Metrolotion® Imiquimod Aldara® 2-octylcyanoacrylate Dermabond Topical Skin Adhesive®Alitretinoin gel 0.1% Panretin®Loratidine Claritin®Cetirizine Zyrtec®Penciclovir Denavir®Lyme disease vaccine LYMErix®